Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Researchers have found that the use of a cell phone technology-based polytherapeutic that delivers white noise can improve symptoms for people suffering from tinnitus.
Roche Wins Approval for Flu Drug in Young Children, Pfizer Touts Positive Results for Infant Vaccine
Roche and Pfizer shared positive news from their respective forays into a new pneumococcal vaccine for infants and a treatment for influenza in small children.
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved by the FDA as the first HER2-directed medicine for the treatment of patients with HER2-mutant metastatic NSCLC.
Two patients receiving Novartis’ SMA gene therapy Zolgensma have died from acute liver failure, the company reported Thursday.
In a small pilot study, the implants were able to restore corneal thickness and curvature to normal levels, and vision outcomes were as good as if human-donated corneas had been used.
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
Scientists from the University of Edinburgh have shown that Terazosin approved for high blood pressure and prostate enlargement could be repurposed for another unlikely indication: ALS.
In a first, Prolacta Bioscience recently published a proof of concept study showing that components of human breast milk can treat the adult microbiome without antibiotics.
This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.
The makers of ranitidine-based products, such as Sanofi, GSK and Haleon, are reeling from lawsuits related to carcinogenic contamination that could result in billions of dollars in damages.
Centessa halted ZF874 following the report of an adverse event that involved elevated liver enzymes in a Phase I study. This is the second development program the company has stopped in as many months.